بدائل البحث:
significant improvements » significant improvement (توسيع البحث)
improvements decrease » improvements increased (توسيع البحث), improvements across (توسيع البحث)
point decrease » point increase (توسيع البحث)
fold decrease » fold increase (توسيع البحث), fold increased (توسيع البحث), fold increases (توسيع البحث)
significant improvements » significant improvement (توسيع البحث)
improvements decrease » improvements increased (توسيع البحث), improvements across (توسيع البحث)
point decrease » point increase (توسيع البحث)
fold decrease » fold increase (توسيع البحث), fold increased (توسيع البحث), fold increases (توسيع البحث)
-
1
-
2
-
3
Summary of post-treatment disease course measures from MDMA-AT publications.
منشور في 2025الموضوعات: -
4
-
5
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
6
-
7
-
8
-
9
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
10
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
11
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: -
12
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
13
-
14
-
15
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
منشور في 2025الموضوعات: -
16
Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides
منشور في 2024"…Among them, W<sub>3</sub>BipY<sub>8</sub>-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W<sub>3</sub>BipY<sub>8</sub> but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W<sub>3</sub>BipY<sub>8</sub>. …"
-
17
-
18
-
19
-
20